Research Papers

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model

Publication: Antimicrobial Agents and Chemotherapy

Author(s): Si-Yang Li, Paul J. Converse, Fabrice Betoudji, Jin Lee, Khisimuzi Mdluli, Anna Upton, Nader Fotouhi, Eric L. Nuermberger

3/2023

Tags: Bedaquiline (TMC-207), BPaL, Clinical Development, Drug Discovery, Linezolid, Preclinical Data, Preclinical Models, Pretomanid/PA-824

Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis

Publication: PLOS Global Public Health

Author(s): Aastha Gupta, Sandeep Juneja, Suvanand Sahu, Mohammed Yassin, Grania Brigden, Eliud Wandwalo, Saurabh Rane, Fuad Mirzayev, Matteo Zignol

11/2022

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Publication: New England Journal of Medicine

Author(s): Francesca Conradie, et al., for the ZeNix Trial Team

9/2022

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, XDR-TB

Budgetary impact of using BPaL for treating extensively drug resistant tuberculosis

Publication: BMJ Global Health

Author(s): Christiaan Mulder, Stephan Rupert, Ery Setiawan, Elmira Mambetova, Patience Edo, Jhon Sugiharto, Sani Useni, Shelly Malhotra, Sarah Cook-Scalise, Imran Pambudi, Abdullaat Kadyrov, Adebola Lawanson, Susan van den Hof, et al

1/2022

Tags: BPaL, MDR-TB, TB Market, XDR-TB

Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

Publication: BMC Public Health

Author(s): S. E. J. van de Berg, P. T. Pelzer, A. J. van der Land, E. Abdrakhmanova, A. Muhammad Ozi, M. Arias, S. Cook-Scalise, G. Dravniece, A. Gebhard, S. Juneja, R. Handayani, D. Kappel, M. Kimerling, I. Koppelaar, S. Malhotra et al

7/2021

Tags: BPaL, MDR-TB, Regimen Change, TB Drug Market, TB Market, XDR-TB

The Clinical Dose of Pretomanid: An Exposure-Response Perspective

Author(s): Jerry R. Nedelman, David H. Salinger, Vishak Subramoney, Rob Woolson, Karen Wade, Mengchun Li, Daniel Everitt, Carl M. Mendel, Mel Spigelman

12/2020

Tags: BPaL, Clinical Development, Nix-TB, Pretomanid/PA-824

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

Publication: The New England Journal of Medicine

Author(s): Francesca Conradie, M.B., B.Ch., Andreas H. Diacon, M.D., Nosipho Ngubane, M.B., B.Ch., Pauline Howell, M.B., B.Ch., Daniel Everitt, M.D., Angela M. Crook, Ph.D., Carl M. Mendel, M.D., Erica Egizi, M.P.H., et al., for the Nix-TB Trial Team*

3/2020

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, Regimen Change, Trial Design, XDR-TB

Daily Dosing for Bedaquiline in Patients with Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann

10/2019

Tags: Bedaquiline (TMC-207), BPaL

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): David H. Salinger, Vishak Subramoney, Daniel Everitt, Jerry R. Nedelman

8/2019

Tags: BPaL, Pharmacokinetics, Pretomanid/PA-824

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Hanbin Li, David H. Salinger, Daniel Everitt, Mengchun Li, Angelo Del Parigi, Carl Mendel, Jerry R. Nedelman

7/2019

Tags: BPaL, Pharmacodynamics, Pretomanid/PA-824

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

Publication: Antimicrobial Agents and Chemotheraphy

Author(s): Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton, Mdluli, Fotouhi, Nuermberger EL

4/2019

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide